Patents by Inventor Li Gan
Li Gan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250199020Abstract: A computer-implemented method of automatically managing calibration of an in-vitro diagnostic (IVD) system comprising executing calibration cycles/procedures comprising using calibration solutions, using a calibration solution comprising a first step of transporting the calibration solution to a measurement unit and a second step of measuring the calibration solution by the measurement unit. For each calibration cycle the method comprises starting repetition of the calibration procedure at the earliest at a start of a buffer time period before expiry of a respective calibration validity period, interrupting the calibration procedure upon receiving an order to execute a sample IVD test and restarting or resuming the calibration procedure after executing the sample IVD test, as long as repetition of the calibration procedure can be restarted or resumed within the buffer time period.Type: ApplicationFiled: December 19, 2024Publication date: June 19, 2025Inventors: Richard Bruckner, Andreas Eicher, Li Gan, Franz Korbinian Schwesig-Stelzer
-
Publication number: 20250163052Abstract: The disclosure relates generally novel inhibitors of human cGAS and methods of treating cGAS-related diseases or disorders in a patient.Type: ApplicationFiled: February 14, 2023Publication date: May 22, 2025Inventors: Subhash Sinha et al., Li Gan, Ravi Kumar Nagiri, Sadaf Amin, Yige Huang
-
Publication number: 20240409890Abstract: Provided herein are iPSC lines engineered to express 4R-tau and 4R-tau carrying the P301S MAPT mutation when differentiated into neurons. 4R-P301S neurons display progressive Tau inclusions upon seeding with Tau fibrils and recapitulate features of tauopathy phenotypes, including shared transcriptomic signatures, autophagic body accumulation, and impaired neuronal activity. A CRISPRi screening of genes associated with Tau pathobiology identified over 500 genetic modifiers of Tau-seeding-induced Tau propagation, including retromer VPS29 and the UFMylation cascade as top modifiers. In AD brains, the UFMylation cascade is altered in neurofibrillary-tangle-bearing neurons. Inhibiting the UFMylation cascade suppressed seeding-induced Tau propagation. Also provided herein is a platform to identify novel therapeutic strategies for 4R tauopathy.Type: ApplicationFiled: June 10, 2024Publication date: December 12, 2024Inventors: Li Gan et al., Shiaoching Gong, Celeste Parra Bravo, Zeping Zhao
-
Publication number: 20220192980Abstract: A cationic hyaluronic acid coated spanlastic, comprising a drug-loaded vesicle. The surface of the drug-loaded vesicle is modified by cationic hyaluronic acid, the drug-loaded vesicle comprises a vesicle membrane and a hydrophobic drug wrapped by the vesicle membrane, and the vesicle membrane comprises a nonionic surfactant and an edge activator.Type: ApplicationFiled: April 2, 2020Publication date: June 23, 2022Applicants: FBC (Shanghai) Pharmaceutical Technology Co., Ltd., Kewpie CorporationInventors: Li GAN, Yang LIU, Hua ZHANG, Yanan WANG, Jinlong YANG
-
Patent number: 10877053Abstract: A method of determining an analyte concentration in a sample by a sensor is disclosed. The method includes analyzing a sample signal generated by the sensor for an analyte being measured. If the sample signal is normal, the method includes comparing the sample signal with a first reference signal of a reference solution measured prior to measuring the sample in order to determine the analyte concentration. If the sample signal is abnormal, the method includes comparing the sample signal with a calculated reference signal point obtained by interpolation between the first reference signal and a second reference signal of the same reference solution measured after measuring the sample. Various methods of determining and handling errors based on signal patterns are also disclosed.Type: GrantFiled: March 5, 2018Date of Patent: December 29, 2020Assignee: Roche Diagnostics Operations, Inc.Inventor: Li Gan
-
Patent number: 10809273Abstract: A method of determining an analyte concentration in a sample by a sensor is disclosed. The method includes analyzing a sample signal generated by the sensor for an analyte being measured. If the sample signal is normal, the method includes comparing the sample signal with a first reference signal of a reference solution measured prior to measuring the sample in order to determine the analyte concentration. If the sample signal is abnormal, the method includes comparing the sample signal with a calculated reference signal point obtained by interpolation between the first reference signal and a second reference signal of the same reference solution measured after measuring the sample. Various methods of determining and handling errors based on signal patterns are also disclosed.Type: GrantFiled: March 5, 2018Date of Patent: October 20, 2020Assignee: Roche Diagnostics Operations, Inc.Inventor: Li Gan
-
Publication number: 20180259543Abstract: A method of determining an analyte concentration in a sample by a sensor is disclosed. The method comprises analyzing a sample signal generated by the sensor for an analyte being measured. If the sample signal is normal, the method comprises comparing the sample signal with a first reference signal of a reference solution measured prior to measuring the sample in order to determine the analyte concentration. If the sample signal is abnormal, the method comprises comparing the sample signal with a calculated reference signal point obtained by interpolation between the first reference signal and a second reference signal of the same reference solution measured after measuring the sample. Various methods of determining and handling errors based on signal patterns are also disclosed.Type: ApplicationFiled: March 5, 2018Publication date: September 13, 2018Applicant: Roche Diagnostics Operations, Inc.Inventor: Li Gan
-
Patent number: 10004753Abstract: The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.Type: GrantFiled: January 15, 2016Date of Patent: June 26, 2018Assignee: The J. David Gladstone InstitutesInventors: Li Gan, Xu Chen, Min Xie, Eric M. Verdin
-
Publication number: 20170368080Abstract: The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.Type: ApplicationFiled: January 15, 2016Publication date: December 28, 2017Inventors: Li Gan, Xu Chen, Min Xie, Eric M. Verdin
-
Patent number: 9585907Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.Type: GrantFiled: April 27, 2015Date of Patent: March 7, 2017Assignee: The J. David Gladstone InstitutesInventor: Li Gan
-
Patent number: 9347085Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.Type: GrantFiled: March 19, 2014Date of Patent: May 24, 2016Assignee: The J. David Gladstone InstitutesInventors: Li Gan, Lennart Mucke
-
Publication number: 20160015733Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.Type: ApplicationFiled: April 27, 2015Publication date: January 21, 2016Inventor: Li Gan
-
Patent number: 9040521Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.Type: GrantFiled: September 15, 2010Date of Patent: May 26, 2015Assignee: THE J. DAVID GLADSTONE INSTITUTESInventor: Li Gan
-
Patent number: 8920835Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.Type: GrantFiled: November 22, 2010Date of Patent: December 30, 2014Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, QILU Pharamceutical Co., Ltd.Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
-
Publication number: 20140234302Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.Type: ApplicationFiled: March 19, 2014Publication date: August 21, 2014Applicant: THE J. DAVID GLADSTONE INSTITUTESInventors: Li Gan, Lennart Mucke
-
Patent number: 8691519Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.Type: GrantFiled: March 19, 2013Date of Patent: April 8, 2014Assignee: The J. David Gladstone InstitutesInventors: Li Gan, Lennart Mucke
-
Patent number: 8420613Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.Type: GrantFiled: November 15, 2007Date of Patent: April 16, 2013Assignee: The J. David Gladstone InstitutesInventors: Li Gan, Lennart Mucke
-
Patent number: 8388953Abstract: The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-? (A?) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant cathepsin B polypeptides that are resistant to inhibition by a cysteine protease inhibitor; as well as nucleic acids encoding the variants, and host cells comprising the nucleic acids.Type: GrantFiled: June 29, 2010Date of Patent: March 5, 2013Assignee: The J. David Gladstone InstitutesInventors: Li Gan, Lennart Mucke, Erik Roberson, Sarah Mueller-Steiner
-
Publication number: 20120301547Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.Type: ApplicationFiled: November 22, 2010Publication date: November 29, 2012Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, QILU PHARMACEUTICAL CO., LTD.Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
-
Publication number: 20120225864Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.Type: ApplicationFiled: September 15, 2010Publication date: September 6, 2012Inventor: Li Gan